| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Nov 2026 | 10-Q |
| 16 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs. Responsibilities currently overseen by the Chief... |
| 15 Oct 2026 | 144 |
| 15 Sep 2026 | 144 |
| 24 Aug 2026 |
8-K: Other Events
On August 24, 2026, Erasca, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation (“FTD”) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. |
| 17 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 |
Form 4: Fuchs Charles S., President, R&D
Granted 1,300,000 Stock option (right to buy) |
| 12 Aug 2026 |
Form 3: Fuchs Charles S., President, R&D
No securities owned |
| 11 Aug 2026 | S-8 |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination |
| 10 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective August 10, 2026, Charles S. Fuchs, M.D., M.P.H., was appointed President, Research & Development of Erasca, Inc. (“the Company”). |
| 21 Jul 2026 | 144 |
| 14 Jul 2026 |
8-K: Other Events
31,428,572 Shares of Common Stock, par value $0.0001 per share |
| 14 Jul 2026 | 424B5 |
Loading...